About us
KHENERFIN
Our Science & Development
Our Focus
For Patients & Families
Working with others
News
Contact
Patient Perspective: A conversation with Philip Yeske, PhD – Science & Alliance Officer, UMDF
find more articles
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease
Khondrion Strengthens Governance with Appointment of Experienced Supervisory Board
Khondrion Appoints Jasper Levink as New CEO to Lead Next Phase of Growth
view all articles
